Barbara Bohn1,2, Peter Bramlage3, Christian Wagner4, Matthias Kaltheuner5, Reinhard Welp6, Stefan Sziegoleit7, Artur Zimmermann8, Hans Martin Reuter9, Michael Hummel10,11, Jörg Gloyer12, Reinhard W Holl13,14, Thomas Danne15. 1. Institut für Epidemiologie und Medizinische Biometrie, ZIBMT, Universität Ulm, Ulm, Deutschland. barbara.bohn@uni-ulm.de. 2. Deutsches Diabetes Zentrum (DZD), München-Neuherberg, Deutschland. barbara.bohn@uni-ulm.de. 3. Institut für Pharmakologie und Präventive Medizin, Mahlow, Deutschland. 4. Forum Diabetologie, Surheim, Deutschland. 5. Gemeinschaftspraxis Kaltheuner - v. Boxberg, Leverkusen, Deutschland. 6. Ambulanz für Diabetologie und Ernährungsmedizin, Knappschaftskrankenhaus, Bottrop, Deutschland. 7. Patienten Praxis Berlin Tempelhof, Berlin, Deutschland. 8. Diabeteszentrum, Bad Aibling, Deutschland. 9. Diabetologische Schwerpunktpraxis, Jena, Deutschland. 10. Diabetologische Schwerpunktpraxis, Rosenheim, Deutschland. 11. Institut für Diabetesforschung, Helmholtz Zentrum München, München, Deutschland. 12. Diabeteszentrum Ludwigsburg, Ludwigsburg, Deutschland. 13. Institut für Epidemiologie und Medizinische Biometrie, ZIBMT, Universität Ulm, Ulm, Deutschland. 14. Deutsches Diabetes Zentrum (DZD), München-Neuherberg, Deutschland. 15. Kinder- und Jugendkrankenhaus "AUF DER BULT", Hannover, Deutschland.
Abstract
BACKGROUND: Glargine U300 (Gla-300) is a further development of glargine U100 (Gla-100). Since 2015, Gla-300 has been available in Germany and Austria. We compared patients initiating therapy with Gla-300 with patients starting with Gla-100. Moreover, it was investigated whether patients from real-life diabetes care differ from patients participating in the EDITION clinical study program. METHODS: Data are based on the diabetes registries DPV and DIVE. Patients started/switched to Gla-100 or Gla-300 in 2015 were included. Linear regression was applied for bodyweight (BW), BMI, HbA1C, daily total and basal insulin dose/kgBW and negative binomial regression for severe hypoglycemia. Data were adjusted for age, sex, and diabetes duration. RESULTS: 14,123 patients were identified (Gla-100: 11,397; Gla-300: 2726). Gla-300 patients with T1D were older, T2D patients younger compared to subjects using Gla-100 (both p < 0.0001). In Gla-300 subjects, diabetes duration was longer (both p < 0.0001). Patients started/switched to Gla-300 had a higher BW, a higher BMI and a lower baseline HbA1C. The rate of severe hypoglycemia was comparable. Total and basal insulin doses/kgBW were higher in patients with Gla-300. DPV/DIVE subjects were older, had a lower BW, and were more frequently male compared to EDITION patients. HbA1C was higher in T1D patients from DPV/DIVE. CONCLUSION: Data from the diabetes registries DPV/DIVE indicate differences between Gla-300 and Gla-100 patients at the onset of insulin therapy. This analysis provides additional information to the EDITION clinical study program.
BACKGROUND:Glargine U300 (Gla-300) is a further development of glargineU100 (Gla-100). Since 2015, Gla-300 has been available in Germany and Austria. We compared patients initiating therapy with Gla-300 with patients starting with Gla-100. Moreover, it was investigated whether patients from real-life diabetes care differ from patients participating in the EDITION clinical study program. METHODS: Data are based on the diabetes registries DPV and DIVE. Patients started/switched to Gla-100 or Gla-300 in 2015 were included. Linear regression was applied for bodyweight (BW), BMI, HbA1C, daily total and basal insulin dose/kgBW and negative binomial regression for severe hypoglycemia. Data were adjusted for age, sex, and diabetes duration. RESULTS: 14,123 patients were identified (Gla-100: 11,397; Gla-300: 2726). Gla-300 patients with T1D were older, T2D patients younger compared to subjects using Gla-100 (both p < 0.0001). In Gla-300 subjects, diabetes duration was longer (both p < 0.0001). Patients started/switched to Gla-300 had a higher BW, a higher BMI and a lower baseline HbA1C. The rate of severe hypoglycemia was comparable. Total and basal insulin doses/kgBW were higher in patients with Gla-300. DPV/DIVE subjects were older, had a lower BW, and were more frequently male compared to EDITION patients. HbA1C was higher in T1D patients from DPV/DIVE. CONCLUSION: Data from the diabetes registries DPV/DIVE indicate differences between Gla-300 and Gla-100 patients at the onset of insulin therapy. This analysis provides additional information to the EDITION clinical study program.
Entities:
Keywords:
Diabetes Registries; Glargine U300; Routine Care; Type 1 Diabetes; Type 2 Diabetes
Authors: Philip D Home; Richard M Bergenstal; Geremia B Bolli; Monika Ziemen; Maria Rojeski; Melanie Espinasse; Matthew C Riddle Journal: Diabetes Care Date: 2015-06-17 Impact factor: 19.112
Authors: Elbert S Huang; Neda Laiteerapong; Jennifer Y Liu; Priya M John; Howard H Moffet; Andrew J Karter Journal: JAMA Intern Med Date: 2014-02-01 Impact factor: 21.873
Authors: T Danne; M Kaltheuner; A Koch; S Ernst; W Rathmann; H-J Rüssmann; P Bramlage Journal: Dtsch Med Wochenschr Date: 2013-04-23 Impact factor: 0.628
Authors: G B Bolli; M C Riddle; R M Bergenstal; M Ziemen; K Sestakauskas; H Goyeau; P D Home Journal: Diabetes Obes Metab Date: 2015-02-12 Impact factor: 6.577
Authors: R Ritzel; R Roussel; G B Bolli; L Vinet; C Brulle-Wohlhueter; S Glezer; H Yki-Järvinen Journal: Diabetes Obes Metab Date: 2015-06-16 Impact factor: 6.577
Authors: Markus Laimer; Andreas Melmer; Julia K Mader; Ingrid Schütz-Fuhrmann; Heide-Rose Engels; Gabriele Götz; Martin Pfeifer; Julia M Hermann; Christoph Stettler; Reinhard W Holl Journal: PLoS One Date: 2016-03-03 Impact factor: 3.240
Authors: Florentino Carral San Laureano; Mariana Tomé Fernández-Ladreda; Ana Isabel Jiménez Millán; Concepción García Calzado; María Del Carmen Ayala Ortega Journal: J Investig Med Date: 2021-03-26 Impact factor: 2.895